TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean Diameter of Erythema at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diameter of Induration at Site of Injection With the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Marrow Response Rate (BMRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Self-Assessment of Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death in hospital within four weeks of injury
Endpoint domain: Mortality/survival
Primary endpoint: Lower limbs pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion with relapse(s) of P. vivax
Endpoint domain: Mortality/survival
Primary endpoint: Progressive Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with grade ≥ 3 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance to heated milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitosterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the ROC curve of serum Procalcitonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drop in end-tidal CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in lung compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in mental state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Service use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Hamilton Anxiety Rating Scale (HAM-A) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUCinf of MDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of MDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of MDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Percent Change in Ki67 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inattention (Parent Rating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperactivity-impulsivity (Parent Rating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inattention (Teacher Rating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperactivity-impulsivity (Teacher Rating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word Reading (WIAT-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pseudoword Decoding (WIAT-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Measurement of Phosphorylated (p)-EGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microorganisms eradication in canal roots
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Daily Oral Vandetanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Daily Oral Bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Response in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression Free Survival in Adults With a Diagnosis of Medullary Thyroid Cancer (MTC)
Endpoint domain: Mortality/survival
Primary endpoint: Chlorzoxazone metabolization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality during hospitalization and follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Evolution of the Liver Frailty Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Bruto muscular efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of sodium and lithium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 500m run time performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metastasis-Free survival (MFS)
Endpoint domain: Mortality/survival
Primary endpoint: Hepatitis B e-Antigen (HBeAg) Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective Response Rate (ORR) for Dose Expansion Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Objective Response (BOR) for Dose Escalation Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) for Extension Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Venous Pressure (CVP) measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of endometrial carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Heavy Drinking Days (PHDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Drinks Per Drinking Day (MDPDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar pliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shrinkage of the thyroid nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time required for parathyroidectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of seizure-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall response rate maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in glycemic control as measured by hemoglobin A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-SSRS (Columbia-Suicide Severity Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HbA1c Level Change Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Interference-Score (I-Score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma NNC0174-0833 concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AIDS-defining and Non-AIDS-defining Malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Clinically Important Hepatic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Clinically Important Skin Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Clinically Important Muscle Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Lipodystrophy
Endpoint domain: Adverse events/effects
Primary endpoint: Jugular bulb oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-specific CD4+ T cell magnitudes of responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-specific CD8+ T cell magnitudes of responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participant Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Initial and absolute claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Days to engraftment defined as absolute neutrophil count (ANC: segs + bands) greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in QoL (POMS-SF, FACT-BMT, CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in cough reflex sensitivity (CRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in depressive symptoms (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in depressive symptoms (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to first bowel movement or flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Measurement of bedsores size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in average QTc intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in scores on the State Anxiety subscale of the STAI-CH
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in physiological stress levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In hospital mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: AHI value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical decision for treatment output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nystagmus response (peak slow phase velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: S. aureus carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SAP index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Beck depression questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tinnitus handicap inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in saccadic eye movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time for Initial Disease Pattern to Appear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: virus-specific T cell-mediated responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-specific B cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: viremia and immune correlates of control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Amygdala Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained Virological Response-HBV DNA<2000IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CK-MB area under the curve within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in depressive symptoms - clinician rated
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histological evaluation of structural repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI assessment of structural repair parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological neurological questionnaire (PNF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression Free Survival Rate at One Year
Endpoint domain: Mortality/survival
Primary endpoint: TNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24 Hour Postoperative Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Level of immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of latent HIV reservoirs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nadir CD4 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantification of thiols membranous on the surface of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HDSS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from Pre-Test to Post-Test treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Load AUC (Day 1 to Day 9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRI estimates of carotid atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-RNA >=50 Copies Per mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-Worsening of ICIQ + Ditrovie Scales' Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First Strike Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Second Strike Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Adaptive Therapy Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of dual energy computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Flap failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Investigator Global Assessment (IGA) Improvement From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Inflammatory Lesion Counts From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: [18F]NOS brain uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with dose limiting toxicities in the first 10 weeks of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who have resectable disease
Endpoint domain: Mortality/survival
Primary endpoint: Endogenous markers of CYP2D6 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Actinic Keratosis (AK) Lesions Cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change in Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BMI Percentile Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 3 or 4 gastro-intestinal or other non-haematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Incontinence Episodes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Criteria for MDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Disease Control (DC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Non-invasive/Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Non-invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Last shock efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported outcome scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to acute hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Acute Hospital Admission, Emergency Room Visit or Death
Endpoint domain: Mortality/survival
Primary endpoint: TBI detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of spontaneous respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the Health Self-Care Neglect (HSCN) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Self-Care Inventory, Maintenance Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discontinuation of study drug due to safety or tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in FSH and LH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Strength of the internal and external rotators of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 30-day all-cause postoperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: HIV Viral Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Müllerian Hormone Levels (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Investigator's Global Assessment Score (IGA score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair Growth Assessment (HGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Scalp Health Assessment (SSHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGI-BP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Effort tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analogue Scale (VAS) of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cognitive Function- CPT-IP D-prime Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Rey Auditory Verbal Learning Test RAVLT (Trial 7)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in AIS Motor and sensory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in ASIA Impairment Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radiation dose measured as Dose-area product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial Serum Inflammatory Cytokine Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak Serum Cytokine Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial Serum Triglyceride Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite event of all-cause death, non-fatal myocardial infarction and repeat revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Patients With Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: fMRI function connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differential gene expression between LS and normal vulvar skin tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential protein expression between LS and normal vulvar skin tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of tissue-derived glycoproteins in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of ability to discriminate time features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to recruit 30 subjects
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients who are eligible who agree to be randomized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients who are lost to follow up or who withdraw from the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of tocolytic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Safe Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes